- GSK Plc's U.S.-listed shares surged Wednesday after the pharmaceutical firm boosted its long-term outlook and launched a $2.5 billion stock buyback on the back of optimism about sales of its new drugs.
- The British drugs giant said it expects 2031 revenue to be more than 40 billion pounds.
- GSK's fourth-quarter core earnings per share and revenue also beat estimates.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.